Previous studies from Blanco’s group demonstrated that a diet incorporating CCR5 antagonist Maraviroc significantly reduced hepatic triglyceride accumulation and steatosis under diet-induced NAFLD [13,14]. The gene discussed is CCR5; the disease is metabolic dysfunction-associated steatotic liver disease.